Table 2.
Annual change in 11C-PBR28 binding from baseline for controls and patients.
| Region | Percent change in 11C-PBR28 binding per year | |||
|---|---|---|---|---|
|
| ||||
| Controls (n = 8) |
Patients (n = 14) |
Progressors (n = 9) |
Non-progressors (n = 5) |
|
|
|
|
|||
| Prefrontal cortex | −0.6% ±1.6% |
2.5% ±5.1% |
3.4% ±6.3% |
0.8% ±1.2% |
| Superior parietal lobule |
0.1% ±1.1% |
3.9% ±4.5%* |
4.2% ±4.8% |
3.4% ±4.6% |
| Inferior parietal lobule | 0.0% ±1.5% |
6.3% ±6.6%* |
8.2% ±7.4% |
2.9% ±2.7% |
| Precuneus | −1.5% ±3.0% |
5.0% ±5.0%* |
6.8% ±5.3% |
1.9% ±2.2%† |
| Occipital cortex | −0.1% ±1.5% |
3.9% ±3.7%* |
4.8% ±4.2% |
2.3% ±2.4% |
| Hippocampus | 0.4% ±4.3% |
4.3% ±3.4%* |
3.8% ±3.1% |
5.3% ±4.0% |
| Entorhinal cortex | −2.2% ±3.3% |
7.7% ±8.5%* |
8.5% ±9.3% |
6.1% ±7.5% |
| Middle and inferior temporal cortex |
−0.5% ±2.0% |
4.7% ±5.3%* |
7.1% ±4.9% |
0.3% ±2.4%†† |
| Superior temporal cortex |
−0.4% ±1.2% |
3.9% ±6.1% |
5.7% ±7.1% |
0.8% ±0.3%† |
*
P < 0.05 patients vs. controls (unpaired t-test, survives False Discovery Rate).
†
P < 0.05 progressors vs. non-progressors (Mann-Whitney U test).
††
P < 0.005 progressors vs. non-progressors (Mann-Whitney U test).
Data given as mean ± SD.